Matches in Wikidata for { <http://www.wikidata.org/entity/Q57105469> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- Q57105469 description "article by Maria Vittoria Dieci et al published October 2018 in Seminars in Cancer Biology" @default.
- Q57105469 description "im Oktober 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q57105469 description "wetenschappelijk artikel" @default.
- Q57105469 description "наукова стаття, опублікована в жовтні 2018" @default.
- Q57105469 name "Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group o" @default.
- Q57105469 name "Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group o" @default.
- Q57105469 type Item @default.
- Q57105469 label "Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group o" @default.
- Q57105469 label "Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group o" @default.
- Q57105469 prefLabel "Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group o" @default.
- Q57105469 prefLabel "Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group o" @default.
- Q57105469 P1433 Q57105469-A4AB7B7E-6B60-41B2-95D4-32CD63CB2102 @default.
- Q57105469 P1476 Q57105469-AE344E87-2ED0-45EE-AF35-BCA0D969EB83 @default.
- Q57105469 P2093 Q57105469-353CF302-A462-4E21-8CA8-6377348D525B @default.
- Q57105469 P2093 Q57105469-4634545F-FD68-4043-A51B-B5B3EDA2D059 @default.
- Q57105469 P2093 Q57105469-46ADA8D3-E973-4582-B874-26EC90414F40 @default.
- Q57105469 P2093 Q57105469-50E13BA0-50BE-46CA-94DD-9E7B99508A4F @default.
- Q57105469 P2093 Q57105469-5774DBBD-5F6D-4CFE-A195-BC806A097AFA @default.
- Q57105469 P2093 Q57105469-5A240CC5-5FF1-4590-89DC-D4BA6DBD92E1 @default.
- Q57105469 P2093 Q57105469-64D62905-2176-4EB8-81A4-97BD88A0E383 @default.
- Q57105469 P2093 Q57105469-67D6C913-6A96-4111-B09D-D3E384A86C56 @default.
- Q57105469 P2093 Q57105469-68140DA9-DE4A-4263-A25D-33E743CDEF42 @default.
- Q57105469 P2093 Q57105469-7BB82A6F-5C2E-4C5C-8EEC-0521B843BFF7 @default.
- Q57105469 P2093 Q57105469-93F0ED12-D33C-4D98-AFAC-3A8485D96319 @default.
- Q57105469 P2093 Q57105469-94D6A078-A24C-4174-926D-0E876316EAFE @default.
- Q57105469 P2093 Q57105469-9642070E-ABC3-4618-B633-2C7F58624837 @default.
- Q57105469 P2093 Q57105469-A8F7559D-87C5-40D4-A24C-04B9D99DA3BB @default.
- Q57105469 P2093 Q57105469-B7C0D7D5-0661-4DBF-A1BD-739F0017CF79 @default.
- Q57105469 P2093 Q57105469-BA23B921-6416-46BD-BB23-F9FDF1F0D035 @default.
- Q57105469 P2093 Q57105469-C346A8A7-0142-4DAA-B349-541BD84EE597 @default.
- Q57105469 P2093 Q57105469-E08987A8-683D-49A3-85EF-F621FBCAB883 @default.
- Q57105469 P2093 Q57105469-E203325D-DE4E-4352-AA76-BBB4F3A6949E @default.
- Q57105469 P2093 Q57105469-EE9E6803-135F-436B-83CC-0A8FF842AC83 @default.
- Q57105469 P2093 Q57105469-F52A7333-0B49-444C-8F83-9D9835F242E1 @default.
- Q57105469 P2093 Q57105469-F7DDEE43-C0F9-44FD-94EE-7A895870ABD1 @default.
- Q57105469 P304 Q57105469-1152EA96-A67D-4FD8-B245-969726D0BC1D @default.
- Q57105469 P31 Q57105469-9D01E1A0-7897-46BC-B863-F99E2E813C6F @default.
- Q57105469 P356 Q57105469-43FBD76E-E00F-47E0-AF13-50331F3F4258 @default.
- Q57105469 P407 Q57105469-D76728D4-513A-495F-98C0-6B7FA2F21272 @default.
- Q57105469 P433 Q57105469-0AE98E93-E78E-4E01-B2E7-01C4C3B8D21D @default.
- Q57105469 P478 Q57105469-48D17298-5162-4F9A-B6B0-2B3752AD6161 @default.
- Q57105469 P50 Q57105469-145A95BC-838B-43D3-9893-0DA23BFDD1D1 @default.
- Q57105469 P50 Q57105469-5ED45ABA-EF5A-4E87-952D-9338F9280118 @default.
- Q57105469 P50 Q57105469-68310C06-F25F-41C5-A210-93F1AACFF2D8 @default.
- Q57105469 P50 Q57105469-6CEA40DE-2059-49F2-8332-F77968CC8C51 @default.
- Q57105469 P50 Q57105469-748C67E3-CF27-4519-918C-DB8A46A3A115 @default.
- Q57105469 P50 Q57105469-753AC5C6-0CF2-4268-843D-06A98F2FB96F @default.
- Q57105469 P50 Q57105469-81187F8A-AC15-4653-A300-BBD3F7F36035 @default.
- Q57105469 P577 Q57105469-A77221A9-74EF-4797-95B6-22E679F37099 @default.
- Q57105469 P698 Q57105469-06DBB1A7-41F3-486E-809B-5E41CD37CE68 @default.
- Q57105469 P921 Q57105469-1E11210F-A229-4978-893E-29D840A27DE5 @default.
- Q57105469 P921 Q57105469-3721E11E-5BC1-469D-91DB-91FE9393E84C @default.
- Q57105469 P921 Q57105469-C4CFE7B4-B026-43D5-97C2-657F568E39C8 @default.
- Q57105469 P921 Q57105469-ED5EEE3C-C9AF-4EF9-BAF8-0C5384E7DBF4 @default.
- Q57105469 P356 J.SEMCANCER.2017.10.003 @default.
- Q57105469 P698 29024776 @default.
- Q57105469 P1433 Q1908668 @default.
- Q57105469 P1476 "Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group o" @default.
- Q57105469 P2093 "Baljit Singh" @default.
- Q57105469 P2093 "Carsten Denkert" @default.
- Q57105469 P2093 "David Rimm" @default.
- Q57105469 P2093 "Fraser Symmans" @default.
- Q57105469 P2093 "Frederique Penault-Llorca" @default.
- Q57105469 P2093 "Gert van den Eynden" @default.
- Q57105469 P2093 "Giancarlo Pruneri" @default.
- Q57105469 P2093 "Giuseppe Viale" @default.
- Q57105469 P2093 "International Immuno-Oncology Biomarker Working Group on Breast Cancer" @default.
- Q57105469 P2093 "Joselyn Sanchez" @default.
- Q57105469 P2093 "Nils Ternes" @default.
- Q57105469 P2093 "Nina Radosevic-Robin" @default.
- Q57105469 P2093 "Roberto Salgado" @default.
- Q57105469 P2093 "Seong-Rim Kim" @default.
- Q57105469 P2093 "Sherene Loi" @default.
- Q57105469 P2093 "Stephan Wienert" @default.
- Q57105469 P2093 "Sunil Badve" @default.
- Q57105469 P2093 "Susan Fineberg" @default.
- Q57105469 P2093 "Sybille Loibl" @default.
- Q57105469 P2093 "Timothy M D'Alfonso" @default.
- Q57105469 P2093 "Torsten Nielsen" @default.
- Q57105469 P2093 "Veerle Bossuyt" @default.
- Q57105469 P304 "16-25" @default.
- Q57105469 P31 Q13442814 @default.
- Q57105469 P356 "10.1016/J.SEMCANCER.2017.10.003" @default.
- Q57105469 P407 Q1860 @default.
- Q57105469 P433 "Pt 2" @default.
- Q57105469 P478 "52" @default.
- Q57105469 P50 Q30361876 @default.
- Q57105469 P50 Q38543969 @default.
- Q57105469 P50 Q41044549 @default.
- Q57105469 P50 Q56891663 @default.
- Q57105469 P50 Q57050061 @default.
- Q57105469 P50 Q57656975 @default.
- Q57105469 P50 Q61766016 @default.
- Q57105469 P577 "2018-10-01T00:00:00Z" @default.
- Q57105469 P698 "29024776" @default.
- Q57105469 P921 Q128581 @default.
- Q57105469 P921 Q16979420 @default.
- Q57105469 P921 Q3421914 @default.
- Q57105469 P921 Q864574 @default.